Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 16/20 | 0.53 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.52 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3223200 | 1.00 | ROCK2 (0.53) | ROCK2MAP2K1ROCK1SMYD3 | |
| SCHEMBL3221797 | 0.91 | MAP2K1 (0.53) | ROCK2MAP2K1ROCK1SMYD3 | |
| SCHEMBL3221806 | 0.91 | MAP2K1 (0.53) | ROCK2MAP2K1ROCK1SMYD3 | |
| SCHEMBL12851227 | 0.90 | MAP2K1 (0.56) | ROCK2MAP2K1ROCK1SMYD3 | |
| SCHEMBL3221655 | 0.90 | MAP2K1 (0.56) | ROCK2MAP2K1ROCK1SMYD3 | |
| SCHEMBL3221643 | 0.90 | MAP2K1 (0.56) | ROCK2MAP2K1ROCK1SMYD3 | |
| SCHEMBL3224890 | 0.89 | MAP2K1 (0.52) | ROCK2MAP2K1ROCK1SMYD3 | |
| SCHEMBL3223776 | 0.89 | MAP2K1 (0.52) | ROCK2MAP2K1ROCK1SMYD3 | |
| SCHEMBL12851268 | 0.88 | MAP2K1 (0.58) | ROCK2MAP2K1ROCK1 | |
| SCHEMBL12851334 | 0.86 | MAP2K1 (0.54) | ROCK2MAP2K1ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2102187-B1 | SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES AS INHIBITORS OF RHO-KINASE | SANOFI SA (FR) | 2015-04-01 | — | — | EP | claimed |
| EP-2102187-B1 | SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES AS INHIBITORS OF RHO-KINASE | SANOFI SA (FR) | 2015-04-01 | — | — | EP | disclosed |
| US-8461144-B2 | Substituted isoquinoline and isoquinolinone derivatives | SANOFI (FR) | 2013-06-11 | — | — | US | disclosed |
| US-20120316152-A1 | SUBSTITUTED ISOQUINOLINEAND ISOQUINOLINONE DERIVATIVES | SANOFI (FR) | 2012-12-13 | — | — | US | disclosed |
| US-8278294-B2 | Substituted isoquinoline and isoquinolinone derivatives as inhibitors of Rho-kinase | SANOFI (FR) | 2012-10-02 | — | — | US | disclosed |
| US-20100063025-A1 | Substituted isoquinoline and isoquinolinone derivatives as inhibitors of RHO-Kinase | SANOFI-AVENTIS (FR) | 2010-03-11 | — | — | US | disclosed |
| EP-2102187-A1 | SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES AS INHIBITORS OF RHO-KINASE | Sanofi-Aventis (FR) | 2009-09-23 | — | — | EP | disclosed |
| WO-2008077550-A1 | SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES AS INHIBITORS OF RHO-KINASE | SANOFI-AVENTIS (FR) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063025-A1 | Substituted isoquinoline and isoquinolinone derivatives as inhibitors of RHO-Kinase | ROCK1, MYLK, ROCK2 | ROCK2 3/4885MAP2K1 909/4885ROCK1 1/4885 |
| US-20120316152-A1 | SUBSTITUTED ISOQUINOLINEAND ISOQUINOLINONE DERIVATIVES | MYLK2, RHOT2, MYLK | ROCK2 9/4885MAP2K1 1731/4885ROCK1 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.